Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Herbert J. Zeh"'
Autor:
Michelle R. Ju, Sam C. Wang, John C. Mansour, Patricio M. Polanco, Adam C. Yopp, Herbert J. Zeh, Matthew R. Porembka
Publikováno v:
JCO Oncology Practice. 18:e748-e758
PURPOSE: Previous studies have shown health disparities among US-Mexico border county (BC) residents. However, the impact of BC residence on gastric cancer treatment and survival outcomes is unknown. Our study compares the receipt of guideline-concor
Autor:
Gilbert Zvikomborero Murimwa, Jennie Meier, Mithin Nehrubabu, Adam C. Yopp, Herbert J. Zeh, Patricio M. Polanco
Publikováno v:
Journal of Clinical Oncology. 41:787-787
787 Background: Social vulnerability is a federal metric used to assess a community’s resilience in facing external stressors from disease or disaster. The social vulnerability index (SVI) includes 15 social factors obtained at the census tract lev
Autor:
Herbert J. Zeh, Jian Han, Aatur D. Singhi, Sagar N Sharma, Amer H. Zureikat, Pranav Murthy, Wenjing Pan, Nathan Bahary, Daniel Weber, Tullia C. Bruno, Miranda Byrne-Steele, Michael T. Lotze
Publikováno v:
Journal of Clinical Oncology. 39:e16001-e16001
e16001 Background: Autophagy is a cell survival mechanism that is upregulated in pancreatic ductal adenocarcinoma (PDAC). PDAC autophagy results in an altered metabolic phenotype that promotes tumor progression, chemotherapeutic resistance, and immun
Autor:
Jordan Berlin, Susan G. Urba, Matthew Mumber, Richard D. Schulick, Pamela B. Mangu, Herbert J. Zeh, Supriya G. Mohile, Marc Shapiro, Theodore S. Hong, Anirban Maitra, Anitra Engebretson, Matthew H.G. Katz, Alok A. Khorana
Publikováno v:
Journal of Clinical Oncology. 34:2541-2556
Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palli
Autor:
Herbert J. Zeh, Amer H. Zureikat, Heather L. Jones, Lekshmi Ramalingam, Sara Alhelo, James F. Pingpank, Steven A. Ahrendt, Matthew P. Holtzman, David L. Bartlett, Carissa A. Low, Haroon A. Choudry, Dana H. Bovbjerg
Publikováno v:
Journal of Clinical Oncology. 34:1217-1222
Purpose The current study examined prospective relationships between preoperative depressive symptoms and short-term (30-day morbidity and readmission) and long-term (overall survival) outcomes after hyperthermic intraperitoneal chemotherapy with cyt
Autor:
Sam C. Wang, James-Michael Blackwell, Matthew R. Porembka, Michelle R. Ju, Adam C. Yopp, Patricio M. Polanco, John C. Mansour, Herbert J. Zeh
Publikováno v:
Journal of Clinical Oncology. 38:2039-2039
2039 Background: The receipt of timely, guideline concordant cancer amongst racial/ethnic and socioeconomic vulnerable populations remains a significant health policy issue. The Affordable Care Act (ACA) with implementation of Medicaid Expansion soug
Autor:
Naomi Fei, Aatur D. Singhi, Pavan Rao, M.E. Hogg, Sijin Wen, Nathan Bahary, Rajesh Ramanathan, Brian A. Boone, Amer H. Zureikat, Herbert J. Zeh, Michael T. Lotze
Publikováno v:
Journal of Clinical Oncology. 38:761-761
761 Background: SMAD4, a tumor suppressor gene, is inactivated or deleted in 60-90% of pancreatic adenocarcinomas (PDA). Loss of SMAD4 allows tumor progression by limiting cell cycle arrest and apoptosis and increasing metastases. SMAD4 deficient PDA
Autor:
Kenneth K. Lee, Adam C. Olson, Jacob C. Hodges, Aatur D. Singhi, Steven A. Burton, Amer H. Zureikat, Asmita Chopra, Herbert J. Zeh, Nathan Bahary, M.E. Hogg, Michael T. Lotze, Brian A. Boone
Publikováno v:
Journal of Clinical Oncology. 38:727-727
727 Background: Neoadjuvant therapy is increasingly used for pancreatic cancer (PDA). The comparative efficacy of neoadjuvant chemotherapy (NC) versus chemoradiation (NCRT) remains uncertain. We aimed to compare NC and NCRT on survival outcomes and p
Autor:
Jennifer N. Uram, Andrea Wang-Gillam, Ed Lemmens, Dung T. Le, Justin Skoble, Deirdre Jill Cohen, Daniel A. Laheru, Beth Onners, Robert L. Fine, Todd S. Crocenzi, Michael A. Morse, John Grous, Tim F. Greten, Herbert J. Zeh, Thomas W. Dubensky, Dirk G. Brockstedt, Vincent J. Picozzi, Sara Solt, Gregory M. Springett, Aimee Murphy, Elizabeth M. Jaffee, Eric R. Lutz
Publikováno v:
Journal of Clinical Oncology. 33:1325-1333
Purpose GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhib
Autor:
Amer H. Zureikat, Patrick R. Varley, Johanna E. Bellon, Connor Buchholz, Melissa E. Hogg, Aatur D. Singhi, Amr I. Al Abbas, Nathan Bahary, Jacob C. Hodges, Herbert J. Zeh
Publikováno v:
Journal of Clinical Oncology. 37:e15724-e15724
e15724 Background: Surgery followed by adjuvant chemotherapy (SF) is the standard approach for localized pancreatic adenocarcinoma (PC). Although neoadjuvant chemotherapy (NC) is being increasingly used, its efficacy remains debatable. This study aim